当前位置： SCI文献检索 > Clinical Colorectal Cancer期刊下所有文献 > Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.

Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.

Abstract：

BACKGROUND:No biomarkers exist to predict benefit from antiangiogenic therapy in metastatic colorectal cancer patients. ACVRL1 (activin receptor like-protein 1) encodes for ALK1, a member of the transforming growth factor-β receptor family, which directs pathologic angiogenesis. We examined the intratumoral expression of ACVRL1 and other angiogenesis pathway-related genes to identify molecular markers in the TRIBE study. MATERIALS AND METHODS:Of 503 randomized patients, 228 had sufficient tissue for analysis. Formalin-fixed paraffin-embedded specimens were examined for expression of VEGF-A, VEGF-B, VEGF-C, VEGFR1, VEGFR2, ACVRL1, EphB4, and EGFL7 using reverse transcription polymerase chain reaction. A maximal χ2 approach was used to determine the messenger RNA levels associated with progression-free survival (PFS), overall survival (OS), response rate, early tumor shrinkage, and depth of response. Recursive partitioning trees were constructed to identify composite prognostic biomarker profiles. External validation was conducted in silico using the Oncomine database. RESULTS:High ACVRL1 expression was associated with superior OS in both treatment arms (FOLFOXIRI [5-fluorouracil, leucovorin, oxaliplatin, irinotecan]-bevacizumab, 32.7 vs. 13.5 months, hazard ratio [HR], 0.38, P = .023; FOLFIRI [5-fluorouracil, leucovorin, irinotecan]-bevacizumab, 35.1 vs. 22.0 months, HR, 0.36, P = .006) and prolonged PFS (11.7 vs. 5.9 months, multivariate HR, 0.17; P = .001) for patients receiving FOLFOXIRI-bevacizumab on univariate and multivariate analyses. In recursive partitioning analysis, ACVRL1 was the strongest discriminator of the response rate, PFS, and OS in patients receiving FOLFOXIRI-bevacizumab and of OS in patients receiving FOLFIRI-bevacizumab. In silico validation revealed significant associations between ACVRL1 expression, disease recurrence, and 1-year survival (P < .05) among all colorectal cancer stages. CONCLUSION:ACVRL1 expression could serve as a prognostic biomarker in metastatic colorectal cancer patients receiving chemotherapy and bevacizumab and warrants further evaluation in prospective studies.

journal_name

Clin Colorectal Cancer

journal_title

Clinical colorectal cancer

authors

Hanna DL,Loupakis F,Yang D,Cremolini C,Schirripa M,Li M,Matsusaka S,Berger MD,Miyamoto Y,Zhang W,Ning Y,Antoniotti C,Salvatore L,Moran M,Zeger G,Astrow SH,Falcone A,Lenz HJ

doi

10.1016/j.clcc.2018.03.006

subject

Has Abstract

pub_date

2018-09-01 00:00:00

pages

e471-e488

issue

3

eissn

1533-0028

issn

1938-0674

pii

S1533-0028(18)30011-2

journal_volume

17

pub_type

杂志文章

相关文献

Clinical Colorectal Cancer文献大全
  • Induction Chemotherapy Reduces Patient-reported Toxicities During Neoadjuvant Chemoradiation with Intensity Modulated Radiotherapy for Rectal Cancer.

    abstract：BACKGROUND:Initial treatment with either neoadjuvant chemoradiation (CRT) or induction FOLFOX (5-Fluorouracil, leucovorin, and oxaliplatin) chemotherapy followed by CRT is considered standard treatment for locally advanced rectal cancer. We compared patient-reported outcomes (PRO) during CRT in patients who had receive...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2019.04.001

    authors： Ng SY,Colborn KL,Cambridge L,Cercek A,Reidy-Lagunes DL,Segal N,Stadler Z,Saltz LB,Paty PB,Guillem J,Weiser MR,Nash G,Garcia-Aguilar J,Goodman KA

    更新日期：2019-09-01 00:00:00

  • Does biomolecular characterization of stage II/III colorectal cancer have any prognostic value?

    abstract：:As new improvements in the treatment of colorectal cancer have become available, it has become important to understand the benefits of new therapies or the deleterious effects stemming from the increased risk of toxicity. In particular, a more rational approach to adjuvant chemotherapy for patients with stage II/III d...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.3816/ccc.2006.n.019

    authors： Funaioli C,Pinto C,Mutri V,Di Fabio F,Ceccarelli C,Martoni AA

    更新日期：2006-05-01 00:00:00

  • Functional imaging of colorectal cancer: positron emission tomography, magnetic resonance imaging, and computed tomography.

    abstract：:In the past 10 years, overall survival and disease-free survival of patients with colorectal cancer (CRC) has improved substantially because of a combination of factors: (1) more accurate staging as a result of advances in imaging technology; (2) refinements in surgical technique; (3) 'curative' metastasectomy for pat...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.3816/CCC.2009.n.013

    authors： Kapse N,Goh V

    更新日期：2009-03-01 00:00:00

  • Locoregional strategies for colorectal hepatic metastases.

    abstract：:Hepatic colorectal metastases present a challenging problem in patients with recurrent colorectal cancer. Twenty percent of patients with recurrence will have liver metastases as a component of their disease, and only 10% of these patients will have isolated liver metastases that are resectable. Although systemic chem...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CCC.2003.n.010

    authors： Meyers MO,Sasson AR,Sigurdson ER

    更新日期：2003-05-01 00:00:00

  • Current approaches to first-line treatment of advanced colorectal cancer.

    abstract：:The multiplicity of chemotherapy regimens currently available to treat colorectal cancer in the first-line setting precludes the identification of a single standard regimen for front-line therapy. The previous standard, 5-fluorouracil (5-FU), formerly the only agent with any significant activity against colorectal can...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.3816/ccc.2004.s.002

    authors： Goldberg RM

    更新日期：2004-06-01 00:00:00

  • Outcome of Molecular Targeted Agents Plus Chemotherapy for Second-Line Therapy of Metastatic Colorectal Cancer: A Meta-Analysis of Randomized Trials.

    abstract：INTRODUCTION:The aim of this study was to evaluate the efficacy and toxicity of molecular targeted agents plus chemotherapy compared with chemotherapy alone as second-line therapy for patients with metastatic colorectal cancer (mCRC). MATERIALS AND METHODS:We identified randomized controlled trials that compared molec...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,meta分析

    doi：10.1016/j.clcc.2016.03.005

    authors： Pei X,Liu Y,Sun L,Zhang J,Fang Y,Liao X,Liu J,Zhang C,Yin T

    更新日期：2016-12-01 00:00:00

  • The Role of the Gut Microbiome in Colorectal Cancer: Where Are We? Where Are We Going?

    abstract：:Microbiome (microbiota) is a community of all microorganisms inhabiting a specific site of the body, including pathogens, which distinguishes it from the physiological microflora. Intestinal dysbiosis plays a key role in the development of colorectal cancer. In the process of carcinogenesis, inflammation, immune respo...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clcc.2019.07.006

    authors： Wieczorska K,Stolarek M,Stec R

    更新日期：2020-03-01 00:00:00

  • Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer.

    abstract：:The discovery of the key role of the epidermal growth factor receptor (EGFR) and its downstream signaling effectors in the pathophysiology of colorectal cancer (CRC) has ushered in the clinical use of targeted therapies in the treatment of metastatic CRC (mCRC). The anti-EGFR monoclonal antibodies cetuximab and panitu...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clcc.2015.05.006

    authors： Lee MS,Kopetz S

    更新日期：2015-12-01 00:00:00

  • COVID-19 and the Global Impact on Colorectal Practice and Surgery.

    abstract：BACKGROUND:The novel severe acute respiratory syndrome coronavirus 2 virus that emerged in December 2019 causing coronavirus disease 2019 (COVID-19) has led to the sudden national reorganization of health care systems and changes in the delivery of health care globally. The purpose of our study was to use a survey to a...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2020.05.011

    authors： Nunoo-Mensah JW,Rizk M,Caushaj PF,Giordano P,Fortunato R,Dulskas A,Bugra D,da Costa Pereira JM,Escalante R,Koda K,Samalavicius NE,Maeda K,Chun HK,ISUCRS COVID-19 Participating Investigator Group.

    更新日期：2020-09-01 00:00:00

  • Intussusception in colorectal cancer.

    abstract：:Adult intussusception is a rare occurrence and, unlike in childhood, is usually associated with an underlying tumor. Although computed tomography (CT) imaging can identify an intussusception and point toward a cause, diagnosis is challenging if it is only intermittent. When an intussusception presents in the context o...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.3816/CCC.2008.n.028

    authors： Chand M,Bradford L,Nash GF

    更新日期：2008-05-01 00:00:00

  • Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine.

    abstract：INTRODUCTION:Coronary vasospasm associated with fluoropyrimidine (FP)-based chemotherapy is a potentially serious complication and reported to occur more often with infusional 5-fluorouracil (5-FU) or capecitabine than with bolus 5-FU. Given the additional benefit of oxaliplatin over FP alone in the management of color...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2018.09.006

    authors： Chakrabarti S,Sara J,Lobo R,Eiring R,Finnes H,Mitchell J,Hartgers M,Okano A,Halfdanarson T,Grothey A

    更新日期：2019-03-01 00:00:00

  • AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer.

    abstract：BACKGROUND:The efficacy and safety of the FOLFIRI (leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin) regimen combined with aflibercept has not been studied in the first-line management of patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS:In the context of a prospective single-arm trial (NC...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clcc.2018.06.003

    authors： Pentheroudakis G,Kotoula V,Koliou GA,Karavasilis V,Samantas E,Aravantinos G,Kalogeropoulou L,Souglakos I,Kentepozidis N,Koumakis G,Sgouros J,Zarkavelis G,Efstratiou I,Laschos K,Petraki C,Tikas I,Poulios C,Voutsina A,G

    更新日期：2018-12-01 00:00:00

  • Adjuvant radiation therapy of patients with rectal cancer.

    abstract：:The standard in rectal cancer has been to add adjuvant radiation therapy to surgery in patients with stage II and III disease. Total mesorectal excision has led to lower local recurrence rates, and, if properly performed, may make adjuvant radiation unnecessary for certain stage II and III patients, such as T3 N0 pati...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CCC.2003.n.002

    authors： Bechtel J,Tepper J

    更新日期：2003-02-01 00:00:00

  • A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer.

    abstract：:This phase II study was designed to characterize the clinical activity of ISIS 3521 in patients with metastatic colorectal cancer (CRC). Sixteen patients with pretreated or refractory CRC were treated with ISIS 3521. Eleven patients were given a dose of 2.0 mg/kg per day, and 5 patients received 3.0 mg/kg per day give...

    journal_title：Clinical colorectal cancer

    pub_type： 临床试验,杂志文章

    doi：10.3816/ccc.2004.n.026

    authors： Marshall JL,Eisenberg SG,Johnson MD,Hanfelt J,Dorr FA,El-Ashry D,Oberst M,Fuxman Y,Holmlund J,Malik S

    更新日期：2004-11-01 00:00:00

  • Preclinical data targeting vascular endothelial growth factor in colorectal cancer.

    abstract：:Vascular endothelial growth factor (VEGF) is the driving force behind angiogenesis in most solid malignancies. This also holds true for colorectal cancer (CRC), where increased levels of VEGF in primary cancers are associated with increased microvessel density and poor prognosis. These findings have led to preclinical...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.3816/ccc.2004.s.009

    authors： Ellis LM

    更新日期：2004-10-01 00:00:00

  • Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysis.

    abstract：BACKGROUND:As of 2006, bevacizumab was available for the treatment of metastatic colorectal cancer (mCRC) in British Columbia (BC). This study compares survival between referred patients diagnosed with mCRC in 2003/2004 (pre-bevacizumab era) and 2006 (bevacizumab era). PATIENTS AND METHODS:The BC cancer agency (BCCA) ...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2011.03.004

    authors： Renouf DJ,Lim HJ,Speers C,Villa D,Gill S,Blanke CD,O'Reilly SE,Kennecke H

    更新日期：2011-06-01 00:00:00

  • Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer.

    abstract：BACKGROUND:ERBB2 amplification occurs in 5% of RAS wild-type metastatic colorectal cancer (mCRC) and it has been shown to be a target for treatment with 2 HER2-directed combinations of trastuzumab and lapatinib or trastuzumab and pertuzumab. We present long-term clinical results of trastuzumab and lapatinib (HERACLES-A...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2020.06.009

    authors： Tosi F,Sartore-Bianchi A,Lonardi S,Amatu A,Leone F,Ghezzi S,Martino C,Bencardino K,Bonazzina E,Bergamo F,Fenocchio E,Martinelli E,Troiani T,Siravegna G,Mauri G,Torri V,Marrapese G,Valtorta E,Cassingena A,Cappello G

    更新日期：2020-12-01 00:00:00

  • Treatment paradigms with epidermal growth factor receptor-targeted therapies in colorectal cancer.

    abstract：:Epidermal growth factor receptor (EGFR) has been validated as an important target in the treatment of metastatic colorectal cancer (mCRC). While initial studies focused on the treatment of disease that was refractory to available chemotherapy agents, 2 recent themes have emerged: the use of KRAS mutation status to sel...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CCC.2010.s.006

    authors： Stein S,Cohen DJ,Hochster HS

    更新日期：2010-06-01 00:00:00

  • Correlation of lactate dehydrogenase isoenzyme profile with outcome in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab or cediranib: Retrospective analysis of the HORIZON I study.

    abstract：INTRODUCTION:Bevacizumab improves outcome for patients with advanced colorectal cancer (CRC) when added to chemotherapy. The HORIZON I trial resulted in similar outcome with bevacizumab or cediranib, a small-molecule tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF) receptor, as treatment of advanc...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.clcc.2013.11.002

    authors： Bar J,Spencer S,Morgan S,Brooks L,Cunningham D,Robertson J,Jürgensmeier JM,Goss GD

    更新日期：2014-03-01 00:00:00

  • Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study.

    abstract：BACKGROUND:The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation (ICECREAM) study assessed the efficacy of cetuximab monotherapy compared with cetuximab combined with chemotherapy for quadruple wild-type (KRAS, NRAS, BRAF, or P13KCA exon 20) metastatic colorectal cancer. PATIENTS AND METHODS:Patients w...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1016/j.clcc.2018.06.002

    authors： Shapiro JD,Thavaneswaran S,Underhill CR,Robledo KP,Karapetis CS,Day FL,Nott LM,Jefford M,Chantrill LA,Pavlakis N,Tebbutt NC,Price TJ,Khasraw M,Van Hazel GA,Waring PM,Tejpar S,Simes J,Gebski VJ,Desai J,Segelov E

    更新日期：2018-12-01 00:00:00

  • Outcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System.

    abstract：BACKGROUND:Metastatic colorectal cancer (CRC) outcomes continue to improve, but they vary significantly by race and ethnicity. We hypothesize that these disparities arise from unequal access to care. MATERIALS AND METHODS:The Harris Health System (HHS) is an integrated health delivery network that provides medical car...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2019.09.002

    authors： Lau-Min K,Prakash P,Jo E,Thrift AP,Hilsenbeck S,Musher BL

    更新日期：2020-06-01 00:00:00

  • Gemcitabine-Related Pneumonitis in Pancreas Adenocarcinoma--An Infrequent Event: Elucidation of Risk Factors and Management Implications.

    abstract：BACKGROUND:Gemcitabine-related pneumonitis (GRP) has been reported relatively frequently for pancreas cancer in the literature; however, underlying risk factors and optimal management remain to be defined. We studied a cohort of patients with GRP and investigated potential predisposing factors in pancreatic cancer pati...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2015.08.003

    authors： Sahin IH,Geyer AI,Kelly DW,O'Reilly EM

    更新日期：2016-03-01 00:00:00

  • Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib.

    abstract：BACKGROUND:Treatment sequencing for patients with refractory metastatic colorectal cancer (mCRC) has been highly debated. The thymidine-based nucleoside trifluridine/tipiracil (TAS-102) and the multikinase inhibitor regorafenib have demonstrated clinical benefits in randomized phase III trials compared with placebo. Ho...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2018.05.012

    authors： Unseld M,Drimmel M,Siebenhüner A,Gleiss A,Bianconi D,Kieler M,Scheithauer W,Winder T,Prager GW

    更新日期：2018-12-01 00:00:00

  • Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration.

    abstract：:This article reviews the current status of the topoisomerase I (top I) inhibitors in the treatment of gastrointestinal (GI) malignancies. We focus on oral drug administration, the mode of administration that is generally preferred by patients with cancer. However, the great majority of the studies have been performed ...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.3816/ccc.2004.n.017

    authors： Kuppens IE,Beijnen J,Schellens JH

    更新日期：2004-09-01 00:00:00

  • A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer.

    abstract：PURPOSE:Capecitabine has shown similar efficacy to 5-fluorouracil (5-FU); a regimen containing 2 weeks of capecitabine/oxaliplatin (CapOx) has demonstrated noninferiority to infusional 5-FU/oxaliplatin/leucovorin (FOLFOX) for the treatment of metastatic colorectal cancer (mCRC). This phase II study explores the efficac...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.3816/CCC.2010.n.021

    authors： Lubner SJ,Loconte NK,Holen KD,Schelman W,Thomas JP,Jumonville A,Eickhoff JC,Seo S,Mulkerin DL

    更新日期：2010-07-01 00:00:00

  • Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study.

    abstract：PURPOSE:The tumor-activated fluoropyrimidine capecitabine achieves response rates superior to those of bolus 5-fluorouracil/leucovorin (5-FU/LV) as first-line treatment for metastatic colorectal cancer (CRC), with favorable safety and fewer hospitalizations. Capecitabine is also at least as effective as bolus 5-FU/LV i...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.3816/ccc.2005.n.021

    authors： Twelves CJ,Butts CA,Cassidy J,Conroy T,Braud Fd,Diaz-Rubio E,Tabernero JM,Schoffski P,Figer A,Brunet R,Grossmann J,Sobrero AF,Van Cutsem EJ

    更新日期：2005-07-01 00:00:00

  • The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.

    abstract：BACKGROUND:Panitumumab, a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR), is used as monotherapy for chemorefractory metastatic colorectal cancer (mCRC) in patients with wild-type (WT) KRAS tumors. Although skin toxicities are the most common adverse events associated with EGFR in...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1016/j.clcc.2011.06.004

    authors： Mitchell EP,Piperdi B,Lacouture ME,Shearer H,Iannotti N,Pillai MV,Xu F,Yassine M

    更新日期：2011-12-01 00:00:00

  • Radiosensitivity of Colon and Rectal Lung Oligometastasis Treated With Stereotactic Ablative Radiotherapy.

    abstract：INTRODUCTION:Patients with metastatic colorectal cancer (CRC) may present with oligometastatic lung lesions for which stereotactic ablative radiotherapy (SABR) can be utilized. This study aims to report efficacy and prognostic factors associated with colorectal lung metastases treated with SABR. MATERIAL AND METHODS:T...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2016.08.003

    authors： Kinj R,Bondiau PY,François E,Gérard JP,Naghavi AO,Leysalle A,Chamorey E,Evesque L,Padovani B,Ianessi A,Benezery K,Doyen J

    更新日期：2017-09-01 00:00:00

  • Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study.

    abstract：BACKGROUND:Metastatic colorectal cancer (mCRC) is increasingly treated using targeted therapies. Their real-life evaluation is insufficient, especially in elderly and frail patients. The aim was to describe use, safety, and effectiveness of targeted therapies in first-line mCRC treatment according to age. PATIENTS AND...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2018.11.005

    authors： Gouverneur A,Coutureau J,Jové J,Rouyer M,Grelaud A,Duc S,Gérard S,Smith D,Ravaud A,Droz C,Bernard MA,Lassalle R,Forrier-Réglat A,Noize P,ETNA study group and the EREBUS study group.

    更新日期：2019-03-01 00:00:00

  • Long-term results of 2 adjuvant trials reveal differences in chemosensitivity and the pattern of metastases between colon cancer and rectal cancer.

    abstract：UNLABELLED:Two identical randomized controlled trials designed to optimize adjuvant treatment of colon cancer (CC) (n =855) and rectal cancer (RC) (n = 796) were performed. Long-term evaluation confirmed that the addition of folinic acid (FA) to 5-fluorouracil (5-FU) improved 7-year overall survival (OS) in CC but not ...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.clcc.2012.07.005

    authors： Kornmann M,Staib L,Wiegel T,Kron M,Henne-Bruns D,Link KH,Formentini A,Study Group Oncology of Gastrointestinal Tumors (FOGT).

    更新日期：2013-03-01 00:00:00